Physician profile
Max Feinstein
NPI 1861839912
$8,045.03
in general payments reported to CMS, 2019-2025
47 companies · $485 in 2025
The $485 reported for 2025 was more than what 79% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $937 · 2021: $1,430 · 2022: $1,206 · 2023: $1,424 · 2024: $1,361 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,269.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $867.85 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $791.34 | 2019-2025 | |
| Novo Nordisk INC | $700.92 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $612.70 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $445.30 | 2019-2024 | |
| Nestle Healthcare Nutrition INC. | $421.70 | 2020-2023 | |
| Lilly USA, LLC | $397.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $395.88 | 2019-2025 | Verquvo |
| Amgen INC. | $280.24 | 2019-2024 | Repatha, Otezla |
| Sumitomo Pharma America, INC. | $222.29 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.49 | 2019-2024 | Trulance, Xifaxan |
| Astellas Pharma US INC | $216.34 | 2019-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $214.17 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.81 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $175.00 | 2020-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Feinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.